What Has Been the Growth of the Amvuttra Market So Far?
The amvuttra market has seen considerable growth due to a variety of factors.
• Recently, the amvuttra market has been expanding at a rate of XX (HCAGR). From 2024 to 2025, it is projected to grow from $XX million to $XX million, yielding a compound annual growth rate (CAGR) of XX%.
Various factors contributing to such growth during the historic period include a spike in transthyretin amyloidosis (ATTR) cases, increased instances of chronic diseases, growing disease awareness, the prevalence of hereditary transthyretin-mediated amyloidosis (hATTR), and a rise in healthcare expenditures.
How Will the Amvuttra Market?
The amvuttra market is expected to maintain its strong growth trajectory in upcoming years.
• For the coming years, the amvuttra market size is projected to witness XX (FCAGR). By 2029, it is expected to reach an impressive sum of $XX million, with an annual compound growth rate (CAGR) of XX%.
This anticipated growth during the forecast period is linked to advancements in RNA interference (RNAi) technology, widening applications, increasing disposable income, heightened awareness and diagnosis of uncommon diseases, government backing, and regulatory rewards. The upcoming period will likely see the evolution of prolonged injectable formulations, a pivot towards tailored and genetic treatments, growing research and development ventures, collaborations with other treatments, and forward strides in telemedicine.
What Key Factors and Trends Are Driving The Growth Amvuttra Market?
The upward trend in the incidence of hereditary transthyretin-mediated amyloidosis (hATTR) is predicted to provide impetus to the expansion of the amvuttra market. hATTR is an uncommon genetic disorder in which transthyretin protein mutations lead to misfolding, creating amyloid deposits that damage multiple organs. An array of factors contribute to the surge in hATTR cases, including an aging demographic, environmental and lifestyle elements, and improvements in genetic testing. Amvuttra efficiently hinders the abnormal production of transthyretin (TTR), mitigating amyloid accumulation and decelerating the disease's advancement in hATTR patients. This therapy has exhibited substantial advantages in relieving symptoms and averting organ damage. For instance, the National Library of Medicine, a US-based biomedical library, reported in October 2022 that about 2.4% of the general populace suffered from peripheral neuropathy, a figure that increased to 8% among the elderly. Consequently, the escalating incidence of hereditary transthyretin-mediated amyloidosis (hATTR) is fueling the expansion of the amvuttra market.
What Key Areas Define The Segmentation Of The Global Amvuttra Market?
The amvuttra market covered in this report is segmented –
1) By Indication: Hereditary Transthyretin-Mediated Amyloidosis (Adult Polyneuropathy, Cardiomyopathy)
2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Adult, Geriatric
Pre-Book The Amvuttra Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Amvuttra Market?
One of the main trends within the amvuttra market revolves around the creation of advanced subcutaneous RNAi therapeutics, with a focus on enhancing the treatment convenience and compliance for hereditary transthyretin-mediated (hATTR) amyloidosis. These groundbreaking advancements are geared towards ensuring less frequent drug administration and maintaining stable drug dispersion, addressing the complications involved in managing enduring conditions like polyneuropathy. For example, in June 2022, leading U.S biopharmaceutical firm, Alnylam Pharmaceuticals, publicized that the U.S. Food and Drug Administration (FDA) gave its approval for the use of AMVUTTRA in the treatment of polyneuropathy in adults suffering from hereditary transthyretin-mediated (hATTR) amyloidosis. AMVUTTRA significantly ameliorates neuropathy symptoms and puts a stop to the progression of the disease. During the HELIOS-A Phase 3 research, over half of the patients saw an arrest or reversal in the disease manifestations. AMVUTTRA boasts a promising safety profile, with zero drug-associated discontinuations or fatalities, and a dosing protocol aimed at boosting patient compliance.
Who Are the Key Players In The Amvuttra Market?
Major companies operating in the amvuttra market include:
• Alnylam Pharmaceuticals Inc.
What Is The Most Dominant Region In The Amvuttra Market?
North America was the largest region in the amvuttra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the amvuttra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
